Show simple item record

End‐stage liver disease candidates at the highest model for end‐stage liver disease scores have higher wait‐list mortality than status‐1A candidates

dc.contributor.authorSharma, Pratimaen_US
dc.contributor.authorSchaubel, Douglas E.en_US
dc.contributor.authorGong, Qien_US
dc.contributor.authorGuidinger, Mary K.en_US
dc.contributor.authorMerion, Robert M.en_US
dc.date.accessioned2012-01-05T22:06:23Z
dc.date.available2013-03-04T15:29:55Zen_US
dc.date.issued2012-01en_US
dc.identifier.citationSharma, Pratima; Schaubel, Douglas E.; Gong, Qi; Guidinger, Mary; Merion, Robert M. (2012). "End‐stage liver disease candidates at the highest model for end‐stage liver disease scores have higher wait‐list mortality than status‐1A candidates ." Hepatology 55(1): 192-198. <http://hdl.handle.net/2027.42/89518>en_US
dc.identifier.issn0270-9139en_US
dc.identifier.issn1527-3350en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/89518
dc.description.abstractCandidates with fulminant hepatic failure (Status‐1A) receive the highest priority for liver transplantation (LT) in the United States. However, no studies have compared wait‐list mortality risk among end‐stage liver disease (ESLD) candidates with high Model for End‐Stage Liver Disease (MELD) scores to those listed as Status‐1A. We aimed to determine if there are MELD scores for ESLD candidates at which their wait‐list mortality risk is higher than that of Status‐1A, and to identify the factors predicting wait‐list mortality among those who are Status‐1A. Data were obtained from the Scientific Registry of Transplant Recipients for adult LT candidates (n = 52,459) listed between September 1, 2001, and December 31, 2007. Candidates listed for repeat LT as Status‐1 A were excluded. Starting from the date of wait listing, candidates were followed for 14 days or until the earliest occurrence of death, transplant, or granting of an exception MELD score. ESLD candidates were categorized by MELD score, with a separate category for those with calculated MELD > 40. We compared wait‐list mortality between each MELD category and Status‐1A (reference) using time‐dependent Cox regression. ESLD candidates with MELD > 40 had almost twice the wait‐list mortality risk of Status‐1A candidates, with a covariate‐adjusted hazard ratio of HR = 1.96 ( P = 0.004). There was no difference in wait‐list mortality risk for candidates with MELD 36‐40 and Status‐1A, whereas candidates with MELD < 36 had significantly lower mortality risk than Status‐1A candidates. MELD score did not significantly predict wait‐list mortality among Status‐1A candidates ( P = 0.18). Among Status‐1A candidates with acetaminophen toxicity, MELD was a significant predictor of wait‐list mortality ( P < 0.0009). Posttransplant survival was similar for Status‐1A and ESLD candidates with MELD > 20 ( P = 0.6). Conclusion : Candidates with MELD > 40 have significantly higher wait‐list mortality and similar posttransplant survival as candidates who are Status‐1A, and therefore, should be assigned higher priority than Status‐1A for allocation. Because ESLD candidates with MELD 36‐40 and Status‐1A have similar wait‐list mortality risk and posttransplant survival, these candidates should be assigned similar rather than sequential priority for deceased donor LT. (H epatology 2012)en_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.titleEnd‐stage liver disease candidates at the highest model for end‐stage liver disease scores have higher wait‐list mortality than status‐1A candidatesen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal MedicineUniversity of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationumDepartment of BiostatisticsUniversity of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationumDepartment of Surgery, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationumAssistant Professor, Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, 3912, Taubman Center, SPC 5362, Ann Arbor, MI 48109en_US
dc.contributor.affiliationotherArbor Research Collaborative for Health, Ann Arbor, MIen_US
dc.identifier.pmid21898487en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/89518/1/24632_ftp.pdf
dc.identifier.doi10.1002/hep.24632en_US
dc.identifier.sourceHepatologyen_US
dc.identifier.citedreferenceUnited Network for Organ Sharing (UNOS)/Organ Procurement and Transplantation Network (OPTN). 3.6 Organ Distribution: Allocation of Livers. Policies. Volume 2011, 2002. http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp. Accessed September 2011.en_US
dc.identifier.citedreferenceKamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end‐stage liver disease. HEPATOLOGY 2001; 33: 464 ‐ 470.en_US
dc.identifier.citedreferenceWiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end‐stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91 ‐ 96.en_US
dc.identifier.citedreferenceWiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7: 567 ‐ 580.en_US
dc.identifier.citedreferenceKremers WK, van IM, Kim WR, Freeman RB, Harper AM, Kamath PS, Wiesner RH. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. HEPATOLOGY 2004; 39: 764 ‐ 769.en_US
dc.identifier.citedreferenceKalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data, 2nd ed. New York: Wiley; 2002.en_US
dc.identifier.citedreferenceSchaubel DE, Guidinger MK, Biggins SW, Kalbfleisch JD, Pomfret EA, Sharma P, et al. Survival benefit‐based deceased‐donor liver allocation. Am J Transplant 2009; 9: 970 ‐ 981.en_US
dc.identifier.citedreferenceFeng S, Goodrich NP, Bragg‐Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783 ‐ 790.en_US
dc.identifier.citedreferenceMerion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307 ‐ 313.en_US
dc.identifier.citedreferenceBerg CL, Steffick DE, Edwards EB, Heimbach JK, Magee JC, Washburn WK, et al. Liver and intestine transplantation in the United States 1998‐2007. Am J Transplant 2009; 9: 907 ‐ 931.en_US
dc.identifier.citedreferenceScientific Registry of Transplant Recipients. 2010 Annual Data Report of the U.S. Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2009.en_US
dc.identifier.citedreferenceHunsicker LG Collins TW, Voigt MD; for the UNOS FNMS>Region 8 Liver Transplant Centers. Outcomes of region‐wide sharing to candidates with MELD >29 in Region 8 [Abstract]. Am J Transplant 2010; 10: 58.en_US
dc.identifier.citedreferenceYantorno SE, Kremers WK, Ruf AE, Trentadue JJ, Podesta LG, Villamil FG. MELD is superior to King's college and Clichy's criteria to assess prognosis in fulminant hepatic failure. Liver Transpl 2007; 13: 822 ‐ 828.en_US
dc.identifier.citedreferenceDhiman RK, Jain S, Maheshwari U, Bhalla A, Sharma N, Ahluwalia J, et al. Early indicators of prognosis in fulminant hepatic failure: an assessment of the Model for End‐Stage Liver Disease (MELD) and King's College Hospital criteria. Liver Transpl 2007; 13: 814 ‐ 821.en_US
dc.identifier.citedreferenceTaylor RM, Davern T, Munoz S, Han SH, McGuire B, Larson AM, et al. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. HEPATOLOGY 2006; 44: 1589 ‐ 1597.en_US
dc.identifier.citedreferenceSchmidt LE, Larsen FS. MELD score as a predictor of liver failure and death in patients with acetaminophen‐induced liver injury. HEPATOLOGY 2007; 45: 789 ‐ 796.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.